Bank of America has moved UnitedHealth Group from Neutral to Buy and increased its price target to $450 from $420 per share, according to a research note published on Thursday. The upgrade was driven by what analyst Kevin Fischbeck described as improving medical-cost trends and a constructive earnings setup heading into the company's second-quarter results.
The new $450 target is derived from 21.4 times BofA's revised 2027 earnings estimates. The firm also notes that its forecasts for both 2026 and 2027 are now above consensus, reflecting an upward revision to expected profitability over the medium term.
"We are upgrading UNH to Buy as improving medical cost trends and supportive near-term data points set up a favorable 2Q earnings setup and attractive risk/reward," Fischbeck wrote in the note.
BofA pointed to a set of incoming utilization indicators that, in the firm's view, make it increasingly difficult to chalk up UnitedHealth's strong first-quarter performance solely to a lighter-than-normal flu season and weather-related effects. The bank cited three items as evidence that cost pressures are easing: its proprietary trend tracker, remarks from company management at a recent conference, and commentary from Ardent Health noting weak utilization in April and May.
Those signals have led BofA to conclude that medical-cost trends continue to moderate. "If utilization trends continue to moderate, UNH - given its bellwether status - should lead a broader MCO rally," Fischbeck wrote, linking UnitedHealth's performance to potential sector-wide upside among managed care organizations.
The note also highlighted the gap between current guidance and the firm's view of underlying earnings power. BofA estimates that UnitedHealth's earnings power sits roughly 50% above its 2026 guidance, and suggested that sustained lower utilization could speed up a return to target margins.
Under the Bank of America scenario, moving toward the low end of UnitedHealth's stated target margins across all business lines by 2028 would imply earnings north of $26 per share, which BofA estimates to be 5-10% above current consensus forecasts.
Despite the upgrade, BofA flagged medium-term risks that could affect the outlook. These include uncertainties around 2028 Medicare Advantage star ratings and rate proposals. The bank said, however, that a recovery in margins would materially reduce the sensitivity of UnitedHealth's results to potential rate pressure.
Context and implications - The Bank of America upgrade rests on multiple near-term utilization indicators and internal trend analysis that together suggest a continuation of moderating medical costs. If those trends persist, BofA expects UnitedHealth to outperform peers and help drive a wider rally in the managed care sector.